MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Vlad Vitoc Buys 72,700 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc bought 72,700 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were purchased at an average cost of $1.39 per share, with a total value of $101,053.00. Following the purchase, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at $1,356,808.19. The trade was a 8.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

MAIA Biotechnology Stock Up 3.8%

Shares of NYSEAMERICAN MAIA opened at $1.35 on Wednesday. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $3.19. The firm has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $1.52. The company has a market capitalization of $82.08 million, a PE ratio of -2.01 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. As a group, equities analysts expect that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Hedge funds have recently bought and sold shares of the company. Marshall Wace LLP bought a new position in MAIA Biotechnology during the second quarter worth $29,000. Ritholtz Wealth Management bought a new position in MAIA Biotechnology during the fourth quarter worth $35,000. Jane Street Group LLC bought a new position in MAIA Biotechnology during the second quarter worth $52,000. Corsair Capital Management L.P. bought a new position in MAIA Biotechnology during the first quarter worth $140,000. Finally, Geode Capital Management LLC grew its holdings in MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares during the period. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.